P21-activated kinase 1 (PAK1) as a therapeutic target in BRAF wild-type melanoma. - Wikidata - awgldk - TriplyDB

P21-activated kinase 1 (PAK1) as a therapeutic target in BRAF wild-type melanoma.

P21-activated kinase 1 (PAK1) as a therapeutic target in BRAF wild-type melanoma.

http://www.wikidata.org/entity/Q39174795

about

Approaches of targeting Rho GTPases in cancer drug discovery Beyond BRAF: where next for melanoma therapy?Targeting Cdc42 in cancer Raf-interactome in tuning the complexity and diversity of Raf function.Small molecule inhibition of group I p21-activated kinases in breast cancer induces apoptosis and potentiates the activity of microtubule stabilizing agents.PAK signalling during the development and progression of cancer Group I PAK inhibitor IPA-3 induces cell death and affects cell adhesivity to fibronectin in human hematopoietic cells A novel compound which sensitizes BRAF wild-type melanoma cells to vemurafenib in a TRIM16-dependent manner Cdk1 phosphorylates the Rac activator Tiam1 to activate centrosomal Pak and promote mitotic spindle formation.Pak2 restrains endomitosis during megakaryopoiesis and alters cytoskeleton organization.Rate-Determining and Rate-Limiting Steps in the Clearance and Excretion of a Potent and Selective p21-Activated Kinase Inhibitor: A Case Study of Rapid Hepatic Uptake and Slow Elimination in Rat.Circulating microRNA-194 regulates human melanoma cells via PI3K/AKT/FoxO3a and p53/p21 signaling pathway.P21-activated kinase in inflammatory and cardiovascular disease.Change or die: targeting adaptive signaling to kinase inhibition in cancer cells.Group I Paks as therapeutic targets in NF2-deficient meningioma.PAK1 is a therapeutic target in acute myeloid leukemia and myelodysplastic syndrome.Potential role of p21 Activated Kinase 1 (PAK1) in the invasion and motility of oral cancer cells.Radiosensitization and downregulation of heterogeneous nuclear ribonucleoprotein K (hnRNP K) upon inhibition of mitogen/extracellular signal-regulated kinase (MEK) in malignant melanoma cells.Overexpression of PAK-1 is an independent predictor of disease recurrence in colorectal carcinoma A new role for cofilin in retinal neovascularization.Synergistic effects of ion transporter and MAP kinase pathway inhibitors in melanoma.PAK4 suppresses PDZ-RhoGEF activity to drive invadopodia maturation in melanoma cells.P21 activated kinases: structure, regulation, and functions.The RhoJ-BAD signaling network: An Achilles' heel for BRAF mutant melanomas Transcriptional regulation of ataxia-telangiectasia and Rad3-related protein by activated p21-activated kinase-1 protects keratinocytes in UV-B-induced premalignant skin lesions.P21-activated kinase 1 regulates resistance to BRAF inhibition in human cancer cells.Targeting PAK1.Integrated genomic analyses reveal frequent TERT aberrations in acral melanoma.PAK1 mediates pancreatic cancer cell migration and resistance to MET inhibition.PAK signalling drives acquired drug resistance to MAPK inhibitors in BRAF-mutant melanomas.Suppression of RAC1-driven malignant melanoma by group A PAK inhibitors.Clinical and pathological associations of the activating RAC1 P29S mutation in primary cutaneous melanoma.Melanoma-associated mutants within the serine-rich domain of PAK5 direct kinase activity to mitogenic pathways.Group I Paks are essential for epithelial- mesenchymal transition in an Apc-driven model of colorectal cancer Macrocyclic lactones inhibit nasopharyngeal carcinoma cells proliferation through PAK1 inhibition and reduce in vivo tumor growth

P2860

Q26851300-32080131-1D60-4F8C-86BA-473B38A1D14D Q27006853-944F241D-D14B-43EA-A48D-2BA7DE18694A Q27028075-0638025D-70AE-4B45-BEA2-18B7C46178DB Q27692653-86BDA6AD-6D80-4675-A947-DC957BBF0322 Q28261026-F8AE9780-2FF3-4358-98F4-94BAFAF41332 Q28307460-93A1E4E4-EFFF-4D84-9E96-7C8BE14D1008 Q28541395-BAFE7EAB-C6B9-4B30-97AC-12E1628026DB Q28817145-76A9E16E-0B89-4311-8440-E1E956C173A7 Q30656511-FA6B315C-CD9E-43FF-A791-F43738ADA0D2 Q33421593-FF6CE5CE-2589-4FAA-8996-4414DE8FE871 Q33604851-C5ACD7C2-18AB-4AB5-B705-70492AFB6B04 Q33674106-EAC8CFAC-EFCE-4459-896B-B0B3C643FF96 Q34032604-EF22F90D-C98E-46AE-9CEF-8DBEEFF279F6 Q34225871-B02D50AE-F715-4C25-B411-9042E3FFCA20 Q35273319-99866513-DAB7-4EDB-9389-6625CB3AF11A Q36000867-738B7ED4-438B-4F58-82CC-B1C2BE6DEC70 Q36031247-D2B43600-0811-48BA-BF1D-5BEF896B0DDD Q36232000-C89E114B-EE08-4EB1-BE2C-26324334DEF4 Q36511751-3A116E74-26FA-44B7-AF4E-AF2943CC8B0E Q36743883-08D75904-C8A2-4D63-88D2-A7A07325CE15 Q37201739-964FCB25-876C-48A4-A8A9-E575B81A0E9E Q37688629-C231D96D-21B8-47A6-A31D-4CB46DC3A10D Q38198494-2FF2E880-7F85-4021-AEB5-CCBF3EF7185D Q38696187-17BD2D08-3571-4C8C-BA87-E530FB065AB1 Q38697741-0AF804FC-E492-4BB8-ACAE-62D051C22A95 Q38722990-EB477AA4-FA27-4B3E-9B40-273468AD14D9 Q38757029-EDF93D59-3D23-487F-A2A2-DE1DA8DE3343 Q41642490-C9D0B83F-B6A6-461C-A297-0955AA6CB053 Q41994295-E6C7B364-03CA-43CF-BFEF-70580F85516B Q47736652-5B1A47FE-180D-4C8E-AFEF-76A6120C3C88 Q47742602-648E54F1-E4F6-4EE1-9762-DEAA5FF78AC4 Q53777162-8ADF8537-F591-47A5-8E2C-DCA1E18B50B1 Q54976847-38ACB4A1-ED04-41C4-84EA-EB8268FEA0A9 Q57980063-BB9C73C7-AAC6-4AF5-A827-2DF5A5757A32 Q58759078-381F253E-5C5A-475C-8AB2-3C9D838DB9CA

P2860

P21-activated kinase 1 (PAK1) as a therapeutic target in BRAF wild-type melanoma.

http://www.wikidata.org/entity/Q39174795

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

2013年论文

@zh

2013年论文

@zh-cn

name

P21-activated kinase 1 (PAK1) as a therapeutic target in BRAF wild-type melanoma.

@en

P21-activated kinase 1

@nl

type

label

P21-activated kinase 1 (PAK1) as a therapeutic target in BRAF wild-type melanoma.

@en

P21-activated kinase 1

@nl

prefLabel

P21-activated kinase 1 (PAK1) as a therapeutic target in BRAF wild-type melanoma.

@en

P21-activated kinase 1

@nl

P1433

Q39174795-453610A7-158B-4F3F-831B-C25563BF4C73

P1476

Q39174795-700896E1-48D4-45BC-923A-9BB97659876F

P2093

Q39174795-00EF9231-D45C-44BF-B64F-B5D1C40C37B4

Q39174795-0D47E9B3-8F5A-4EB9-8260-CBEC4D8B7C56

Q39174795-1099D8A0-CB31-4A9F-B714-DF52D6C42FE0

Q39174795-2A90E8F7-F2D1-4D2D-AA39-9F3D017C9830

Q39174795-3417C366-37C4-4407-BBAA-55037D28C7ED

Q39174795-55730233-9C5C-480B-B8DA-123163549147

Q39174795-6BDF130A-ECDC-4AFE-ADA7-184E002CD0EE

Q39174795-972D6E3D-9C35-4449-96E5-2632D29FA0B0

Q39174795-BB764FBF-0EEE-492A-94C4-CBEE0410C021

Q39174795-C21CA0B1-9EAD-46C7-A125-A08F107398C4

P2860

Q39174795-07DB580A-00CF-4ED4-8E9E-AB7E2FCB637D

Q39174795-09EB8A34-0C63-4F96-887D-5E7B9C636E67

Q39174795-0ADBE155-1255-4474-8C2C-D7BFF1EA9480

Q39174795-0D6E4818-69F4-472B-821D-7008E1638C12

Q39174795-11A13A56-A403-47A1-A778-D7CC80D19F74

Q39174795-24DCEF77-EBD2-4692-A952-333E03B7B301

Q39174795-2ACD449B-ACDE-41C0-BB01-8420ADCF3BBC

Q39174795-2D805487-9931-4D80-9D58-ABE6A99A0822

Q39174795-3FFAAFD3-60AF-484F-9BFD-35482F9E7297

Q39174795-4A9BE9F3-3574-4885-9774-5FF66D59AABC

P304

Q39174795-05E084F5-0B68-4482-904B-AEBEEC8D6DA4

P31

Q39174795-14F1E110-5584-4D42-A0A9-6BFB2515716A

P356

Q39174795-E889E393-826B-42CD-8585-5C6BF89025A5

P407

Q39174795-B431C7E2-5B7F-42F1-B1C2-C9D0DBF288CF

P433

Q39174795-F6013695-EBB9-4974-BDFC-D4B1ACEDA9EE

P478

Q39174795-0D74D82E-2C7C-480C-B125-BC90C9BFFFC6

P50

Q39174795-89603D7B-BBDE-4F63-AEB8-7E584BA57D98

P577

Q39174795-14BE13BE-1C24-429F-AD6D-9F69D15798EA

P5875

Q39174795-011071A6-58FF-43D9-BD0D-43D91DA9EAE3

P698

Q39174795-F07982C7-1E8E-4F16-9785-46F45F7359B3

P356

P1433

Journal of the National Cancer Institute

P1476

P21-activated kinase 1 (PAK1) as a therapeutic target in BRAF wild-type melanoma.

@en

P2093

Adrian M Jubb

http://www.w3.org/2001/XMLSchema#string

Christy C Ong

http://www.w3.org/2001/XMLSchema#string

Diana Jakubiak

http://www.w3.org/2001/XMLSchema#string

Elizabeth M Blackwood

http://www.w3.org/2001/XMLSchema#string

Hartmut Koeppen

http://www.w3.org/2001/XMLSchema#string

Jarrod Tremayne

http://www.w3.org/2001/XMLSchema#string

Joachim Rudolph

http://www.w3.org/2001/XMLSchema#string

Klaus P Hoeflich

http://www.w3.org/2001/XMLSchema#string

Lori S Friedman

http://www.w3.org/2001/XMLSchema#string

Marcia Belvin

http://www.w3.org/2001/XMLSchema#string

P2860

Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF

Serine and tyrosine phosphorylations cooperate in Raf-1, but not B-Raf activation

Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma

A landscape of driver mutations in melanoma

Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity

RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth

Small-molecule p21-activated kinase inhibitor PF-3758309 is a potent inhibitor of oncogenic signaling and tumor growth

Frequencies of BRAF and NRAS mutations are different in histological types and sites of origin of cutaneous melanoma: a meta-analysis.

P304

606-607

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/JNCI/DJT054

http://www.w3.org/2001/XMLSchema#string

P407

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

105

http://www.w3.org/2001/XMLSchema#string

P50

Adrian L Harris

P577

2013-03-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

236086568

http://www.w3.org/2001/XMLSchema#string

P698

23535073

http://www.w3.org/2001/XMLSchema#string